This evolution brings to light the international CMS classification, that clustered CRC into 4 distinct consensus molecular subtypes (CMS): CMS1 (MSI Immune), hypermutated, microsatellite unstable, BRAFV600E mutated, with strong immune activation; CMS2 (Canonical), epithelial, chromosomally unstable, with marked WNT and MYC signaling activation; CMS3 (Metabolic), epithelial, with evident metabolic dysregulation; and CMS4 (Mesenchymal), prominent TGF-β activation, stromal invasion, and angiogenesis. This evidence concerns the gene TGFB1 and colorectal carcinoma.